Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer

Gynecologic Oncology

Volumn 61, Issue 2, 1996, Pages 215-217

  Gadducci, Angiolo ^a   Marrai, Roberto ^a   Baicchi, Ugo ^b   Gagetti, Ornella ^a   Facchini, Virgilio ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; PROTHROMBIN; THROMBIN;

ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 0029959998     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0127     Document Type: Article

References (22)

1. Rickles, F. R., and Edwards, R. L. Activation of blood coagulation in patients with cancer: Trousseau's syndrome revisited, Blood 62, 14-31 (1983).
2. Patterson, W. P. Coagulation and cancer: An overview, Semin. Oncol. 17, 137-139 (1990).
3. Gordon, S. G., and Cross, B. A. A factor X-activating cysteine protease from malignant tissue, J. Clin. Invest. 67, 1665-1672 (1981).
4. Rickles, F. R., Hancock, W. W., Edwards, R. L., and Zacharski, L. R. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment, Semin. Thromb. Hemostasis 14, 88-94 (1988).
5. Luzzatto, G., and Schafer, A. I. The prethrombotic state in cancer, Semin. Oncol. 17, 147-159 (1990).
6. Zacharski, L. R., Wojtukiewicz, M. Z., Costantini, V., Ornstein, D. L., and Memoli, V. A. Pathways of coagulation/fibrinolysis activation in malignancy, Semin. Thromb. Hemostasis 18, 104-116 (1992).
7. Nanninga, P. B., van Teunenbroek, A., Veenhof, C. H. N., Buller, H. R., and ten Cate, J. W. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer, Thromb. Haemostasis 64, 361-364 (1990).
8. Bick, R. L. Coagulation abnormalities in malignancy: A review, Semin. Thromb. Hemostasis 18, 353-372 (1992).
9. Peuscher, F. W., Cleton, F. J., Armstrong, L., Stoepman-van Dalen, E. A., van Mourik, J. A., and van Aken, W. G. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy, J. Lab. Clin. Med. 96, 5-14 (1980).
10. Rickles, F. R., Edwards, R. L., Barb, C., and Cronlund, M. Abnormalities of blood coagulation in patients with cancer: Fibrinopeptide A generation and tumor growth, Cancer 51, 301-307 (1983).
11. Schrock, R., Hafter, R., Graeff, H., and Schmid, L. Die simultane bestimmung von CA-125 und D-dimer in plasma und aszites beim ovarialkarzinom, Gakologie 8, 260-262 (1985).
12. Hafter, R., Schrock, R., Von Hugo, R., and Graeff, H. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D-dimer using EIA and latex test, Scand. J. Clin. Lab. Invest. 45, 137-144 (1985).
13. Khoo, S. K., Rylatt, D. B., Parsons, P., Wilson, K., Webb, M. J., Dickie, G., Kearsley, J., and Mackay, E. V. Serial D-dimer levels in the assessment of tumor mass and clinical outcome in ovarian cancer, Gynecol. Oncol. 29, 188-198 (1988).
14. Gadducci, A., Baicchi, U., Del Bravo, B., Marrai, R., Vispi, M., Fosella, P. V., and Fioretti, P. The assessment of the hemostasis system in patients with ovarian and cervical carcinoma, Cancer J. 4, 183-187 (1991).
15. Gadducci, A., Baicchi, U., Marrai, R., Facchini V., Del Bravo, B., Fosella, P. V., and Fioretti, P. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: Influence of surgical-pathological stage, tumor size, histologic type, and lymph node status, Gynecol. Oncol. 49, 354-358 (1993).
16. Gadducci, A., Baicchi, U., Marrai, R., Del Bravo, B., Fosella, P. V., and Facchini, V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma, Gynecol. Oncol. 53, 352-356 (1994).
17. Pelzer, H., and Stuber, W. Markers of haemostatic activation: new perspectives using immunochemical methods for determination of prothrombin fragment F1+2 and thrombin-antithrombin III complex, Thromb. Haemostasis 62, 165, (1989).
18. Teitel, J. M., Bauer, K. A., Lau, H. K., and Rosenberg, R. D. Studies of the prothrombin activation pathway utilizing radioimmunoassay for the F2/F1+2 fragment and thrombin-antithrombin complex, Blood 59, 1086-1097 (1982).
19. Tatra, G., and Reinthaller, A. Thrombin-antithrombin III complex concentrations in patients with gynaecological malignancy, Klin. Woochenschr. 69, 124-127 (1991).
20. Hanzal, E., and Tatra, G. Prothrombin fragment F1+2 plasma concentrations in patients with gynecologic malignancies, Gynecol. Oncol. 49, 373-376 (1993).
21. Pelzer, H., Schwarz, A., and Stuber, W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide, Thromb. Haemostasis 65, 153-159 (1991).
22. Zacharski, L. R., Memoli, V. A., Ornstein, D. L., Rousseau, S. M., Kisiel, W., and Kudryk, B. J. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary, J. Natl. Cancer Inst. 85, 1225-1230 (1993).